Woman with confident smirk
Woman with confident smirk

Choose

Yes

With YESINTEK™, switching to a Stelara® (ustekinumab) biosimilar feels refreshingly familiar1

Woman with confident smirk

YES to a seamless
treatment experience

When you make the switch to YESINTEK, you can expect a familiar experience with the exact same indications and dosage forms as Stelara.1,2

AVAILABLE FOR SUBCUTANEOUS INJECTION1

AVAILABLE FOR
SUBCUTANEOUS INJECTION1

  • 45 mg/0.5 mL single-dose vial
  • 45 mg/0.5 mL and 90 mg/mL single-dose prefilled syringes

AVAILABLE FOR INTRAVENOUS INDUCTION1

  • 130 mg/26 mL single-dose vial
YESINTEK prefilled syringe

29G NEEDLE1

Thinner needle size than Stelara

NEEDLE COVER1

Covers the needle for patient safety

MADE WITHOUT 
DRY RUBBER LATEX3

Reduces hypersensitivity reactions

NEEDLE SAFETY GUARD1

Prevents needlestick injuries

CITRATE FREE1

Minimizes injection site pain

YESINTEK prefilled syringe
YESINTEK vial

SAME INDICATIONS AND DOSING AS STELARA1,2

Select a condition below to view dosing

For adults

INDUCTION (IV)*DOSENUMBER OF 130 mg/26 mL 
(5 mg/mL) VIALS
≤55 kg260 mg2
>55 kg to 85 kg390 mg3
>85 kg520 mg4
MAINTENANCE (SC)
90 mg every 8 weeks

*Body weight of patient at the time of dosing.
IV=intravenous; SC=subcutaneous.

Patients switching from Stelara to YESINTEK do not need to repeat the one-time IV induction dose and should transition at the next scheduled maintenance dose.

For adults

INDUCTION (IV)*DOSENUMBER OF 130 mg/26 mL 
(5 mg/mL) VIALS
≤55 kg260 mg2
>55 kg to 85 kg390 mg3
>85 kg520 mg4
MAINTENANCE (SC)
90 mg every 8 weeks

*Body weight of patient at the time of dosing.
IV=intravenous; SC=subcutaneous.

Patients switching from Stelara to YESINTEK do not need to repeat the one-time IV induction dose and should transition at the next scheduled maintenance dose.

For adults & children 6 years and older

MAINTENANCE (SC) FOR ADULTS*RECOMMENDED DOSE
≤100 kg45 mg
>100 kg90 mg
MAINTENANCE (SC) FOR PEDIATRICS 6-17 YEARS*RECOMMENDED DOSE
<60 kg0.75 mg/kg
60 kg to 100 kg45 mg
>100 kg90 mg

*Body weight of patient at the time of dosing.

Administer YESINTEK subcutaneously (SC) at Weeks 0 and 4,
then every 12 weeks thereafter.

For adults & children 6 years and older

MAINTENANCE (SC) FOR ADULTS*RECOMMENDED DOSE
45 mg
>100 kg with coexistent

moderate to severe plaque psoriasis		90 mg
MAINTENANCE (SC) FOR PEDIATRICS 6-17 YEARS*RECOMMENDED DOSE
<60 kg0.75 mg/kg
≥60 kg45 mg
>100 kg with coexistent
moderate to severe plaque psoriasis		90 mg

*Body weight of patient at the time of dosing.

Administer YESINTEK subcutaneously (SC) at Weeks 0 and 4,
then every 12 weeks thereafter.

For adults

INDUCTION (IV)*
≤55 kg
DOSE
260 mg
NUMBER OF 130 mg/26 mL (5 mg/mL) VIALS
2
INDUCTION (IV)*
>55 kg to 85 kg
DOSE
390 mg
NUMBER OF 130 mg/26 mL (5 mg/mL) VIALS
3
INDUCTION (IV)*
>85 kg
DOSE
520 mg
NUMBER OF 130 mg/26 mL (5 mg/mL) VIALS
4
MAINTENANCE (SC)
90 mg every 8 weeks

Patients switching from Stelara to YESINTEK do not need to repeat the one-time IV induction dose and should transition at the next scheduled maintenance dose.

*Body weight of patient at the time of dosing.
IV=intravenous; SC=subcutaneous.

For adults

INDUCTION (IV)*
≤55 kg
DOSE
260 mg
NUMBER OF 130 mg/26 mL (5 mg/mL) VIALS
2
INDUCTION (IV)*
>55 kg to 85 kg
DOSE
390 mg
NUMBER OF 130 mg/26 mL (5 mg/mL) VIALS
3
INDUCTION (IV)*
>85 kg
DOSE
520 mg
NUMBER OF 130 mg/26 mL (5 mg/mL) VIALS
4
MAINTENANCE (SC)
90 mg every 8 weeks

Patients switching from Stelara to YESINTEK do not need to repeat the one-time IV induction dose and should transition at the next scheduled maintenance dose.

*Body weight of patient at the time of dosing.
IV=intravenous; SC=subcutaneous.

For adults & children 6 years and older

MAINTENANCE (SC) FOR ADULTS*
≤100 kg
RECOMMENDED DOSE
45 mg
MAINTENANCE (SC) FOR ADULTS*
>100 kg
RECOMMENDED DOSE
90 mg
MAINTENANCE (SC) FOR PEDIATRICS 6-17 YEARS*
<60 kg
RECOMMENDED DOSE
0.75 mg/kg
MAINTENANCE (SC) FOR PEDIATRICS 6-17 YEARS*
60 kg to 100 kg
RECOMMENDED DOSE
45 mg
MAINTENANCE (SC) FOR PEDIATRICS 6-17 YEARS*
>100 kg
RECOMMENDED DOSE
90 mg

Administer YESINTEK subcutaneously (SC) at Weeks 0 and 4,
then every 12 weeks thereafter.

*Body weight of patient at the time of dosing.

For adults & children 6 years and older

MAINTENANCE (SC) FOR ADULTS*
RECOMMENDED DOSE
45 mg
MAINTENANCE (SC) FOR ADULTS*
>100 kg with coexistent moderate
to severe plaque psoriasis
RECOMMENDED DOSE
90 mg
MAINTENANCE (SC) FOR PEDIATRICS 6-17 YEARS*
<60 kg
RECOMMENDED DOSE
0.75 mg/kg
MAINTENANCE (SC) FOR PEDIATRICS 6-17 YEARS*
<60 kg
RECOMMENDED DOSE
45 mg
MAINTENANCE (SC) FOR PEDIATRICS 6-17 YEARS*
>100 kg with coexistent moderate
to severe plaque psoriasis
RECOMMENDED DOSE
90 mg

Administer YESINTEK subcutaneously (SC) at Weeks 0 and 4, then every 12 weeks thereafter.

*Body weight of patient at the time of dosing.

YES to proven clinical biosimilarity

You can prescribe YESINTEK with confidence because it works as well and is as safe as Stelara.1,2,4

View Clinical Data

YESINTEK IS SIMILAR TO STELARA WHERE IT MATTERS3

  • Highly similar pharmacokinetics
  • Highly similar efficacy
  • Highly similar safety profile
  • Highly similar immunogenicity

YES to solid savings 
and support


We’ll give you access to tools and resources to help make it easier for you and your patients to get started with YESINTEK.

Access Resources
Young man laughing

The answer is

Woman smiling and looking up

Yes

Biosimilars aren’t just what we do—they’re all we do.

Biocon Biologics is fully committed to being a global leader in biosimilars. By delivering affordable access to high-quality biosimilars such as YESINTEK around the world, Biocon Biologics aims to help make a meaningful difference for you and your patients.

Learn more about us at 

BioconBiologicsUS.com
Learn more about us at BioconBiologicsUS.com

Learn more about us at BioconBiologicsUS.com ->

Woman smiling and looking up

REFERENCES

1. YESINTEK. Prescribing information. Biocon Biologics Inc; 2024. 2. STELARA. Prescribing information. Janssen Pharmaceutical Companies; 2024. 3. Data on file. Biocon Biologics; 2024. 4. US Food and Drug Administration. Biosimilars: review and approval. Last updated December 13, 2022. Accessed March 11, 2024. https://www.fda.gov/drugs/biosimilars/review-and-approval

INDICATIONS AND IMPORTANT SAFETY INFORMATION

READ MORE +

SHOW LESS -

IMPORTANT SAFETY INFORMATION

Contraindications
YESINTEK is contraindicated in patients with clinically significant hypersensitivity to ustekinumab or to any of the excipients.
Infections
YESINTEK may increase the risk of infections and reactivation of latent infections. Serious bacterial, mycobacterial, fungal, and viral infections in patients receiving ustekinumab.
Serious infections requiring hospitalization or otherwise clinically significant infections:

  • Plaque Psoriasis: diverticulitis, cellulitis, pneumonia, appendicitis, cholecystitis, sepsis, osteomyelitis, viral infections, gastroenteritis, and urinary tract infections.
  • Psoriatic arthritis: cholecystitis.
  • Crohn’s disease: anal abscess, gastroenteritis, ophthalmic herpes zoster, pneumonia, and Listeria meningitis.
  • Ulcerative colitis: gastroenteritis, ophthalmic herpes zoster, pneumonia, and listeriosis.

Treatment with YESINTEK should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated. Consider the risks and benefits of treatment prior to initiating use of YESINTEK in patients with a chronic infection or a history of recurrent infection.
Instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur while on treatment with YESINTEK and discontinue YESINTEK for serious or clinically significant infections until the infection resolves or is adequately treated.
Theoretical Risk for Vulnerability to Particular Infections Individuals genetically deficient in IL-12/IL-23 are particularly vulnerable to disseminated infections from mycobacteria, Salmonella, and Bacillus Calmette-Guerin (BCG) vaccinations. Serious infections and fatal outcomes have been reported in such patients.
It is not known whether patients with pharmacologic blockade of IL-12/IL-23 from treatment with ustekinumab may be susceptible to these types of infections. Consider diagnostic testing, e.g., tissue culture, stool culture, as dictated by clinical circumstances.
Pre-Treatment Evaluation of Tuberculosis (TB) Evaluate patients for TB prior to initiating treatment with YESINTEK.
Do not administer YESINTEK to patients with active tuberculosis infection. Initiate treatment of latent TB before administering YESINTEK. Closely monitor patients receiving YESINTEK for signs and symptoms of active TB during and after treatment.
Malignancies: YESINTEK is an immunosuppressant and may increase the risk of malignancy. Malignancies were reported among patients who received ustekinumab in clinical trials.
The safety of ustekinumab has not been evaluated in patients who have a history of malignancy or who have a known malignancy.
There have been reports of the rapid appearance of multiple cutaneous squamous cell carcinomas in patients receiving ustekinumab who had risk factors for developing non-melanoma skin cancer (NMSC).
All patients receiving YESINTEK, especially those >60 years of age, those with a history of PUVA or prolonged immunosuppressant treatment, should be monitored for the appearance of NMSC.
Hypersensitivity Reactions: Hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with ustekinumab. If an anaphylactic or other clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue YESINTEK.
Posterior Reversible Encephalopathy Syndrome (PRES): Two cases of posterior reversible encephalopathy syndrome (PRES), also known as Reversible Posterior Leukoencephalopathy Syndrome (RPLS), were reported in clinical trials. Cases have also been reported in post-marketing experience in patients with psoriasis, psoriatic arthritis and Crohn’s disease. Clinical presentation included headaches, seizures, confusion, visual disturbances, and imaging changes consistent with PRES a few days to several months after ustekinumab initiation. A few cases reported latency of a year or longer. Patients recovered with supportive care following withdrawal of ustekinumab.
Monitor all patients treated with YESINTEK for signs and symptoms of PRES. If PRES is suspected, promptly administer appropriate treatment and discontinue YESINTEK.
Immunizations Prior to initiating therapy with YESINTEK, patients should receive all age-appropriate immunizations as recommended by current immunization guidelines. Patients being treated with YESINTEK should avoid receiving live vaccines. Avoid administering BCG vaccines during treatment with YESINTEK or for one year prior to initiating treatment or one year following discontinuation of treatment. Caution is advised when administering live vaccines to household contacts of patients receiving YESINTEK because of the potential risk for shedding from the household contact and transmission to patient.
Non-live vaccinations received during a course of YESINTEK may not elicit an immune response sufficient to prevent disease.
Noninfectious Pneumonia Cases of interstitial pneumonia, eosinophilic pneumonia, and cryptogenic organizing pneumonia have been reported during post-approval use of ustekinumab. Clinical presentations included cough, dyspnea, and interstitial infiltrates following one to three doses. Serious outcomes have included respiratory failure and prolonged hospitalization. Patients improved with discontinuation of therapy and, in certain cases, administration of corticosteroids. If diagnosis is confirmed, discontinue YESINTEK and institute appropriate treatment.
Allergen Immunotherapy YESINTEK may decrease the protective effect of allergen immunotherapy (decrease tolerance) which may increase the risk of an allergic reaction to a dose of allergen immunotherapy. Therefore, caution should be exercised in patients receiving or who have received allergen immunotherapy, particularly for anaphylaxis.
Most Common Adverse Reactions

  • Psoriasis: nasopharyngitis, upper respiratory tract infection, headache, and fatigue.
  • Crohn’s Disease, induction: vomiting.
  • Crohn’s Disease, maintenance: nasopharyngitis, injection site erythema, vulvovaginal candidiasis/mycotic infection, bronchitis, pruritus, urinary tract infection, and sinusitis.
  • Ulcerative colitis, induction: nasopharyngitis.
  • Ulcerative colitis, maintenance: nasopharyngitis, headache, abdominal pain, influenza, fever, diarrhea, sinusitis, fatigue, and nausea.

INDICATIONS

YESINTEK (ustekinumab-kfce) is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy; active psoriatic arthritis (PsA); moderately to severely active Crohn’s disease (CD); moderately to severely active ulcerative colitis.
Pediatric patients 6 years and older with: moderate to severe plaque psoriasis, who are candidates for phototherapy or systemic therapy; active psoriatic arthritis (PsA).

INDICATIONS AND IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION

Contraindications
YESINTEK is contraindicated in patients with clinically significant hypersensitivity to ustekinumab or to any of the excipients.
Infections
YESINTEK may increase the risk of infections and reactivation of latent infections. Serious bacterial, mycobacterial, fungal, and viral infections in patients receiving ustekinumab.
Serious infections requiring hospitalization or otherwise clinically significant infections:

  • Plaque Psoriasis: diverticulitis, cellulitis, pneumonia, appendicitis, cholecystitis, sepsis, osteomyelitis, viral infections, gastroenteritis, and urinary tract infections.
  • Psoriatic arthritis: cholecystitis.
  • Crohn’s disease: anal abscess, gastroenteritis, ophthalmic herpes zoster, pneumonia, and Listeria meningitis.
  • Ulcerative colitis: gastroenteritis, ophthalmic herpes zoster, pneumonia, and listeriosis.

Treatment with YESINTEK should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated. Consider the risks and benefits of treatment prior to initiating use of YESINTEK in patients with a chronic infection or a history of recurrent infection.
Instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur while on treatment with YESINTEK and discontinue YESINTEK for serious or clinically significant infections until the infection resolves or is adequately treated.
Theoretical Risk for Vulnerability to Particular Infections Individuals genetically deficient in IL-12/IL-23 are particularly vulnerable to disseminated infections from mycobacteria, Salmonella, and Bacillus Calmette-Guerin (BCG) vaccinations. Serious infections and fatal outcomes have been reported in such patients.
It is not known whether patients with pharmacologic blockade of IL-12/IL-23 from treatment with ustekinumab may be susceptible to these types of infections. Consider diagnostic testing, e.g., tissue culture, stool culture, as dictated by clinical circumstances.
Pre-Treatment Evaluation of Tuberculosis (TB) Evaluate patients for TB prior to initiating treatment with YESINTEK.
Do not administer YESINTEK to patients with active tuberculosis infection. Initiate treatment of latent TB before administering YESINTEK. Closely monitor patients receiving YESINTEK for signs and symptoms of active TB during and after treatment.
Malignancies: YESINTEK is an immunosuppressant and may increase the risk of malignancy. Malignancies were reported among patients who received ustekinumab in clinical trials.
The safety of ustekinumab has not been evaluated in patients who have a history of malignancy or who have a known malignancy.
There have been reports of the rapid appearance of multiple cutaneous squamous cell carcinomas in patients receiving ustekinumab who had risk factors for developing non-melanoma skin cancer (NMSC).
All patients receiving YESINTEK, especially those >60 years of age, those with a history of PUVA or prolonged immunosuppressant treatment, should be monitored for the appearance of NMSC.
Hypersensitivity Reactions: Hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with ustekinumab. If an anaphylactic or other clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue YESINTEK.
Posterior Reversible Encephalopathy Syndrome (PRES): Two cases of posterior reversible encephalopathy syndrome (PRES), also known as Reversible Posterior Leukoencephalopathy Syndrome (RPLS), were reported in clinical trials. Cases have also been reported in post-marketing experience in patients with psoriasis, psoriatic arthritis and Crohn’s disease. Clinical presentation included headaches, seizures, confusion, visual disturbances, and imaging changes consistent with PRES a few days to several months after ustekinumab initiation. A few cases reported latency of a year or longer. Patients recovered with supportive care following withdrawal of ustekinumab.
Monitor all patients treated with YESINTEK for signs and symptoms of PRES. If PRES is suspected, promptly administer appropriate treatment and discontinue YESINTEK.
Immunizations Prior to initiating therapy with YESINTEK, patients should receive all age-appropriate immunizations as recommended by current immunization guidelines. Patients being treated with YESINTEK should avoid receiving live vaccines. Avoid administering BCG vaccines during treatment with YESINTEK or for one year prior to initiating treatment or one year following discontinuation of treatment. Caution is advised when administering live vaccines to household contacts of patients receiving YESINTEK because of the potential risk for shedding from the household contact and transmission to patient.
Non-live vaccinations received during a course of YESINTEK may not elicit an immune response sufficient to prevent disease.
Noninfectious Pneumonia Cases of interstitial pneumonia, eosinophilic pneumonia, and cryptogenic organizing pneumonia have been reported during post-approval use of ustekinumab. Clinical presentations included cough, dyspnea, and interstitial infiltrates following one to three doses. Serious outcomes have included respiratory failure and prolonged hospitalization. Patients improved with discontinuation of therapy and, in certain cases, administration of corticosteroids. If diagnosis is confirmed, discontinue YESINTEK and institute appropriate treatment.
Allergen Immunotherapy YESINTEK may decrease the protective effect of allergen immunotherapy (decrease tolerance) which may increase the risk of an allergic reaction to a dose of allergen immunotherapy. Therefore, caution should be exercised in patients receiving or who have received allergen immunotherapy, particularly for anaphylaxis.
Most Common Adverse Reactions

  • Psoriasis: nasopharyngitis, upper respiratory tract infection, headache, and fatigue.
  • Crohn’s Disease, induction: vomiting.
  • Crohn’s Disease, maintenance: nasopharyngitis, injection site erythema, vulvovaginal candidiasis/mycotic infection, bronchitis, pruritus, urinary tract infection, and sinusitis.
  • Ulcerative colitis, induction: nasopharyngitis.
  • Ulcerative colitis, maintenance: nasopharyngitis, headache, abdominal pain, influenza, fever, diarrhea, sinusitis, fatigue, and nausea.

INDICATIONS

YESINTEK (ustekinumab-kfce) is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy; active psoriatic arthritis (PsA); moderately to severely active Crohn’s disease (CD); moderately to severely active ulcerative colitis.
Pediatric patients 6 years and older with: moderate to severe plaque psoriasis, who are candidates for phototherapy or systemic therapy; active psoriatic arthritis (PsA).

Scroll to Top

You are now leaving www.YESINTEKHCP.com, a Biocon Biologics website. The website you are about to access is not owned or controlled by Biocon Biologics Inc.

Biocon Biologics Inc. assumes no responsibility for and makes no warranties or representation of any kind as to the accuracy, currency, or completeness of any information contained in such third-party website, including any third-party social media or mobile application platform. Inclusion of any third-party link on this website does not imply an endorsement or recommendation by Biocon Biologics, and a link to this website from another website does not imply a relationship between Biocon Biologics and any third party. Your use of any such third-party site or platform is at your own risk and will be governed by such third party’s terms and policies (including its privacy policy). Biocon Biologics shall not be liable for any direct, indirect, consequential, incidental or punitive damages arising out of access to, use of, or inability to use such third-party website, or any errors or omissions in the content thereof.

OK
CANCEL

Enroll Your Patient Today

Download the <Yesintek Copay Assistance Program> Enrollment and Prescription Form

Download the
<Yesintek Copay Assistance Program> Enrollment and Prescription Form

Then fax your completed form to 1-<XXX-XXX-XXXX>.

Download the Form

You can also e-prescribe your YESINTEK prescription by searching for <NAME TBD> in your EHR.* Be sure to include your patient’s mobile number.†

*<ADDRESS TBD>

†By providing the patient’s phone number, you represent that your patient is aware of the disclosure and has given consent to be contacted 
 regarding this prescription, and by the fulfillment pharmacy.

EHR=electronic health record.

INDICATIONS

YESINTEK (ustekinumab-kfce) is a human interleukin-12 and -23 antagonist indicated for the treatment of:

  • Adult patients with:
  • moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy
  • active psoriatic arthritis (PsA)
  • moderately to severely active Crohn’s disease (CD)
  • moderately to severely active ulcerative colitis
  • Pediatric patients 6 years and older with:
  • moderate to severe plaque psoriasis, who are candidates for phototherapy or systemic therapy
  • active psoriatic arthritis (PsA)